Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges

Eli Lilly raised its full-year revenue forecast and beat third-quarter earnings ​expectations on Thursday, propelled by surging demand for injectable weight-loss drugs that could allay investor concerns about price erosion in US government health ‌plans.

Reuters • 13 hours ago

Eli Lilly hikes sales outlook, as CEO says there's room for ‘dramatic' obesity market expansion

Eli Lilly on Thursday reported third-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared again.

CNBC • 13 hours ago

Eli Lilly Sells 53% More at Lower Prices: Rapid Earnings Reaction

Eli Lilly's third-quarter revenue rose 39% to about $24.4 billion, as a 53% jump in volume more than offset a 15% drop in realized prices. Part of the quarter won't repeat, and deal charges are weighing on earnings.

The Motley Fool • 5 hours ago

Big, fat demand for weight-loss drugs fuels Eli Lilly stock surge — as market cap hits $1.2 trillion

Eli Lilly stock hit a record high Thursday thanks to a stronger-than-expected earnings report fueled by sales of weight loss drugs Monjuaro and Zepbound.

New York Post • 7 hours ago

Eli Lilly Blows Past Sales Expectations And Hikes Outlook On Mounjaro, Zepbound Dominance

Eli Lilly blew past sales expectations Thursday and hiked its outlook on the back of strong performance from Mounjaro and Zepbound.

Investors Business Daily • 11 hours ago

Eli Lilly's blowout quarter has a $5.5 billion twist

Eli Lilly LLY reported better-than-expected earnings for its fiscal Q3 on Thursday, offering fresh evidence that helps justify its trillion-dollar market cap. Sales reached $24.4 billion, while adjusted earnings came in at $7.48.

Invezz • 12 hours ago

Lilly raises outlook for third time this year as Zepbound sales soar.

The drug continues do dominate the market for prescription weight-loss drugs in the U.S.

Market Watch • 13 hours ago

Eli Lilly CEO Dave Ricks on the obesity market: The room for expansion is dramatic

Eli Lilly, Dave Ricks joins 'Squawk on the Street' to discuss the company blowing past estimates, hike in sales outlook, and growing demand for weight-loss medication.

CNBC Television • 10 hours ago

Eli Lilly Revenue Climbs on Demand for Mounjaro, Zepbound

The pharmaceutical company's third-quarter profit came in at $6.45 billion, or $7.22 a share, compared with $5.58 billion, or $6.21 a share, a year earlier.

WSJ • 13 hours ago

Eli Lilly Stock Jumps as Monster Earnings Powered by Mounjaro and Zepbound

Eli Lilly posts earnings that handily top estimates, fueled by strong performance in its metabolic portfolio.

Barrons • 13 hours ago